Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This MOU with Coastar is heating up imo:
This is the 3rd time they have Tweeted about it, and referenced the PR.
Discover the power within: From editing genes to enhancing delivery, discover how red blood cells are revolutionizing medicine.
— SOHM, Inc. (@sohminc) May 1, 2024
Click through to the press release:https://t.co/xsAsgwgizY#GeneEditing #RedBloodCells #MedicalInnovation $SHMN#biotech #cancerresearch #invivo… pic.twitter.com/mUUnJxgiaf
Once they file an Attorney Letter, it will take a day or two to get back to Current. It's been a long standing irritation to me that all these companies wait til the last minute to file the Annual, then the last minute to file the Attorney Letter.
The year ended 4 months ago, this last minute stuff doesn't have to happen, but some of them never learn, they'll take every minute, and then some.
Respects.
Put down your highlighter, and go look at his resume on LinkedIn....Then tell me if you're impressed with the guy. The fact that he's here and Tweeting anything related to $shmn is a good thing, imo.
Unless you'd like to post your personal Twitter profile here, and your LinkedIn resume showing your stellar scientific credentials? I know you won't, but then again, I won't either. :)
hL. Shmn
— Mark S (@DrMarkScience) April 30, 2024
Guess who replied to this Tweet?
— Mark S (@DrMarkScience) April 30, 2024
Did you know red blood cell membranes can be used to deliver gene editing tools safely into our cells? This innovative approach could revolutionize treatments for genetic disorders! #GenomeEditing #HealthInnovation $SHMN pic.twitter.com/GsFk6IyNQX
— SOHM, Inc. (@sohminc) April 30, 2024
Looks more like impatient traders to me. Selling to break even and send their money elsewhere. Maybe they can't see the bids at .0011... the 1Q is coming in 2 weeks, even if there's no news to pacify them.
In Aguilars recent interview, he hinted at 'more info to come.' Who knows what it will be, but I'm banking on this being a good start to 2024 for them.
HL. SHMN
Yup and 2 weeks to the 1Q 2024. :)
HL. Shmn. Baby pharma at .0012. :)
Got me a couple of those today. :)
Attorney Letter with Respect to Current Information: https://www.otcmarkets.com/otcapi/company/financial-report/399370/content
The company has published, the Attorney Letter with Respect to Current Information.https://t.co/awlhs6KCI3 $SHMN
— SOHM, Inc. (@sohminc) April 28, 2024
AGBA Congrats, what a move over a few days.
hL
Good weekend all, Gin n tonics. (lots of lime) :)
That's what I thought. :) Good weekend.
On or about Jan 11, 2024, and Jan 24, 2024, other reorganizational events occurred. In conjunction with a loan default of HIRU relating to the water packing business division the financier exercised their default remedies and sold part of the note in
collection in an off the market private transaction to two separate nonrelated entities.
01/11/2024 New Issuance 260,000,000 Common Red Rock Fund Corp.
01/24/2024 New Issuance 250,000,000 Common GB II., Inc.
Notwithstanding the creditor has legal possession of the water equipment, the water equipment remains in HIRU possession, and the relationship is civil and non-adversary. The Company has agreed with the financier that once the equipment is sold (which value is far greater than the loan amount) any surplus from the sale will be returned to the Company.
https://www.otcmarkets.com/otcapi/company/financial-report/398157/content
These are the Professionals at the $SHMN helm:
In no particular order...They can bring it home, imo.
Mark Stevens, Science Advisor:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174197635
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174136261
https://www.linkedin.com/in/mark-stevens-phd-810167a/
Eddie Chung, Coastar CEO:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174150084
"This marks a thrilling juncture for both companies and the realm of gene editing," stated Eddie Chung, CEO of Coastar. "We're intrigued by the precision and integrase capabilities presented by the ABBIE system. This partnership will yield a novel platform applicable in both laboratory and clinical use."
https://coastartherapeutics.com/about-us/
https://www.globenewswire.com/news-release/2024/04/01/2855240/0/en/SOHM-Inc-and-Coastar-Therapeutics-Sign-MoU-and-Announce-Collaboration-to-Revolutionize-Genome-Editing-Using-Red-Blood-Cell-Membrane-Derived-Carriers.html
Tony Tontat, Strategic Financial Analyst:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173733984
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173582848
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173546689
Alfred Gallegos, SHMN Research Scientist:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173660637
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173660026
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173659156
https://www.otcmarkets.com/stock/SHMN/news/SOHM-Collaborates-with-University-of-Arizona-Center-for-Innovation-to-Advance-ABBIE-a-Groundbreaking-Non-Viral-Gene-Edit?id=416912
Eric Furman, Ph.D. Knobbe Martens Sohm Intellectual Property Attorney:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173289185
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173246026
Wm. Dewey Rushing, VP of Quality Sohm:
https://www.linkedin.com/in/wm-dewey-rushing-7505a95/
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173082914
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173082680
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173031688
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172828177
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172794328
https://www.otcmarkets.com/stock/SHMN/news/SOHM-Inc-Announces-the-Appointment-of-Wm-Dewey-Rushing-as-VP-of-Quality-with-Immediate-Effect?id=413696
https://www.otcmarkets.com/stock/SHMN/news/SOHM-Inc-Announces-the-Appointment-of-Wm-Dewey-Rushing-former-US-FDA-Investigator-to-its-Advisory-Board?id=344969
Dr. Krishna Bhatt, Chief Medical Advisor, Bioscientist and Cardiologist:
Current owner of 82 Million Common shares, and recent Preferred Shares in exchange for Funding.
https://www.otcmarkets.com/otcapi/company/financial-report/396087/content
https://www.biomedwire.com/leadership-changes-at-sohm-inc-shmn-to-strengthen-growth-strategies-for-generic-drug-market-and-gene-editing-platform-development/
https://www.otcmarkets.com/stock/SHMN/news/SOHM-Inc-Expands-Its-Advisory-Board-Appointing-Dr-Krishna-Bhat-MD-PhD-FACC-as-Chief-Medical-Advisor?id=411792
Dr. David Aguilar, Sohm Chief Operating Officer:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172703663
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172599661
https://www.otcmarkets.com/stock/SHMN/news/SOHM-Inc-Announce-the-Appointment-of-Dr-David-Aguilar-PhD-as-a-Chief-Operating-Officer-with-the-Company-with-Immediate-E?id=410079
https://www.otcmarkets.com/stock/SHMN/news/SOHM-Inc-Expands-Advisory-Board-with-Appointment-of-Dr-David-Aguilar-PhD-as-its-Expert-Medical-Advisor?id=346149
We’re thrilled to announce that our presentation at #AACR was met with an exceptional reception. It was an honor to showcase our technology to esteemed researchers and leaders in the biotech industry.
— SOHM, Inc. (@sohminc) April 9, 2024
The overwhelming interest and impact generated by our innovation have been… pic.twitter.com/50Ggv6hqPj
Join COO David Aguilar Ph.D., Research Scientist Alfred Gallegos, and Science Advisor Mark Stevens at #AARC2024 to discover our groundbreaking gene-editing platform that will revolutionize how we treat Colon Cancer.
— SOHM, Inc. (@sohminc) March 28, 2024
More: https://t.co/tcmjjGEEW1#SOHMInc #ABBIE $SHMN pic.twitter.com/RzYwx8X4yy
After a successful visit to Japan, our COO, Dr. David Aguilar is back and here are couple pictures of him working at Carlsbad facility with production in-charge.
— SOHM, Inc. (@sohminc) January 25, 2024
Secondly, we are glad to share that we are working with multiple companies for CDMO services and production at the… pic.twitter.com/Wj5qUGgpRe
We are happy where things are today with the Year-end FDA approval of our Carlsbad manufacturing facility which will set our company up for a bright 2024 outlook.$SHMN pic.twitter.com/tehLBtiVNs
— SOHM, Inc. (@sohminc) December 31, 2023
All good ones. He was a wizzard. Lost him way too early.
Urock will soon be We rock. (RJD)
hL gdvm
Tweet/Link to article on Linkedin:
Discover the 9 trends changing the future of medicine and transforming pharmaceuticals
— SOHM, Inc. (@sohminc) April 15, 2024
Check out: https://t.co/yxIsQnKs5S $SHMN #PharmacyTrends #MedicineTrends pic.twitter.com/J1bVfl6NbA
Lots of good technical information in this post.
Thank you. hL shmn
Hey Jeff I think she bought them as documented on Twitter:
...but IMO, then she sold them, on Oct 13, 2023, or thereabouts...
There was a single trade that went off on that date for over 20,000,000 shares (ish.)
I'm not sure if anyone else thinks the same, but when it was obvious that everything was unraveling, and Miro was playing hardball around that date, and airing out the laundry on Twitter...IMO that's when she cashed in the chips. Purely imo, no facts to back up my opinion, but if ever there was a court case to find out the facts, I'd be interested to know when the shares went "back to market." I have no idea the ramifications if this happened, haven't researched.
https://www.barchart.com/stocks/quotes/HIRU/technical-chart?plot=CANDLE&volume=total&data=DO&density=X&pricesOn=1&asPctChange=0&logscale=0&indicators=BBANDS(20,2);PTP(50);STOSL(14,3);STOFA(14,3);RSI(14,100);CHKMF(20);CHKMF(10);CHKOSC;ACCUM;OBV;MFI(14,100);SMA(20);SMA(50);MACD(12,26,9);SMA(200)&sym=HIRU&grid=1&height=500&studyheight=200
Respects. hL
He liked your Tweet:
Good to see you out putting in the work unlike other #OTC pinks with someone behind a keyboard all day adding shares. $SHMN
— TraderBill (@1technicaltrade) April 10, 2024
Agree, Apparently "mum's the word" on San Diego.
San Diego entered into a vortex. Update needed. :)
Good to see Stallion Labs facility, and that we're still exclusive distributor for them with LEVETiracetam in the U.S.
"Revenue Outlook: Anticipate substantial revenue growth in the upcoming second quarter and beyond."
hL shmn
LEVETIRACETAM, Excellent!
Introducing SOHM’s Levetiracetam Tablets: Empowering Seizure Control and Freedom.
— SOHM, Inc. (@sohminc) April 10, 2024
We are thrilled to unveil SOHM’s Levetiracetam tablets—a high-quality generic alternative meticulously crafted for effective seizure management. These tablets, manufactured by Stallion Laboratories… pic.twitter.com/BSDxwT9pCk
Thank you to everyone who stopped by to learn more about ABBIE at #AACR2024! It was an honor to showcase our groundbreaking work.
— SOHM, Inc. (@sohminc) April 10, 2024
Explore more about ABBIE here: https://t.co/tcmjjGEEW1
#$SHMN #AACR2024 #coloncancer pic.twitter.com/6ajJVmw3m2
"We’re thrilled to announce that our presentation at #AACR was met with an exceptional reception. It was an honor to showcase our technology to esteemed researchers and leaders in the biotech industry.
The overwhelming interest and impact generated by our innovation have been truly remarkable.
Stay tuned for more updates following the conclusion of the conference."
Conference Concludes tomorrow the 10th. Should have another update soon. Glad it's going well.
hL shmn
Nice Tweet update on AACR:
We’re thrilled to announce that our presentation at #AACR was met with an exceptional reception. It was an honor to showcase our technology to esteemed researchers and leaders in the biotech industry.
— SOHM, Inc. (@sohminc) April 9, 2024
The overwhelming interest and impact generated by our innovation have been… pic.twitter.com/50Ggv6hqPj
Mark Stevens, Science Advisor at today's AACR Presentation:
Anyone here have such a resume?
Endorsed by various Employees and Colleagues at Merck, Genentech, Astrazeneca, and GlaxoSmithKline.
https://www.linkedin.com/in/mark-stevens-phd-810167a/details/skills/
Join COO David Aguilar Ph.D., Research Scientist Alfred Gallegos, and Science Advisor Mark Stevens at #AARC2024 to discover our groundbreaking gene-editing platform that will revolutionize how we treat Colon Cancer.
— SOHM, Inc. (@sohminc) March 28, 2024
More: https://t.co/tcmjjGEEW1#SOHMInc #ABBIE $SHMN pic.twitter.com/RzYwx8X4yy
Madguppy, welcome, see below if helpful:
5 days to go!
— SOHM, Inc. (@sohminc) April 3, 2024
We're all set for our big reveal at #AACR2024 that can revolutionize colon cancer treatment.
More: https://t.co/tcmjjGEEW1$SHMN #SOHMInc #CancerResearch #ABBIE #ColonCancer pic.twitter.com/BCuV7f0wvV
Witness a paradigm shift at #AARC2024 as we unveil our groundbreaking gene-editing platform! It will revolutionize colon cancer treatment.
— SOHM, Inc. (@sohminc) March 25, 2024
More: https://t.co/tcmjjGEEW1 pic.twitter.com/I6gqBkOMFA
Join COO David Aguilar Ph.D., Research Scientist Alfred Gallegos, and Science Advisor Mark Stevens at #AARC2024 to discover our groundbreaking gene-editing platform that will revolutionize how we treat Colon Cancer.
— SOHM, Inc. (@sohminc) March 28, 2024
More: https://t.co/tcmjjGEEW1#SOHMInc #ABBIE $SHMN pic.twitter.com/RzYwx8X4yy
The company is actively exploring, negotiating, and collaborating with several Japanese companies to expand its business.
— SOHM, Inc. (@sohminc) March 19, 2024
This expansion includes the utilization of gene-editing technology called ABBIE, as well as licensing opportunities.
The management remains committed to…
Intellectual Property Assignment to SOHM, Inc.
— SOHM, Inc. (@sohminc) February 29, 2024
SOHM, Inc., a generic pharmaceutical, nutraceutical, cosmeceutical and Biotech firm, had acquired the disruptive stem cell technology and associated patents known as "ABBIE." This acquisition follows a letter of intent signed with…
We are excited to announce that our company will participate in the American Association for Cancer Research (AACR) annual meeting in San Diego from April 5 to April 10, 2024.
— SOHM, Inc. (@sohminc) February 1, 2024
At this internationally attended meeting, we will present our innovative gene-editing system, ABBIE,…
No prob, all the best to you too knife.
hl
New Corrected Tweet looks like they changed the wording:
I can see why that change needed to be made. :)
5 days to go!
— SOHM, Inc. (@sohminc) April 3, 2024
We're all set for our big reveal at #AACR2024 that can revolutionize colon cancer treatment.
More: https://t.co/tcmjjGEEW1$SHMN #SOHMInc #CancerResearch #ABBIE #ColonCancer pic.twitter.com/BCuV7f0wvV
"The transaction's closing is contingent upon satisfactory due diligence, definitive agreements and is slated to close by March 31, 2024."
https://www.otcmarkets.com/stock/TDRK/news/Tiderock-Companies-and-MTAG-Composites-to-Merge-to-Create-Global-Materials-Company?id=430884
___
This is all I could find in a brief search about the target date. If someone has more since then in a Tweet or whatever, please post. Maybe they needed a little more time, wouldn't be surprised. Respects all.
Eddie Chung, Coastar CEO: "This marks a thrilling juncture for both companies and the realm of gene editing," stated Eddie Chung, CEO of Coastar. "We're intrigued by the precision and integrase capabilities presented by the ABBIE system. This partnership will yield a novel platform applicable in both laboratory and clinical use."
SOHM, Inc. and Coastar Therapeutics Sign MoU and Announce Collaboration to Revolutionize Genome Editing Using Red Blood Cell Membrane Derived Carriers
https://www.globenewswire.com/news-release/2024/04/01/2855240/0/en/SOHM-Inc-and-Coastar-Therapeutics-Sign-MoU-and-Announce-Collaboration-to-Revolutionize-Genome-Editing-Using-Red-Blood-Cell-Membrane-Derived-Carriers.html
2023 Annual Report filed:
https://www.otcmarkets.com/stock/SHMN/disclosure
__
hL
I'm pretty sure this is our Mark Stevens:
"Scientist, Pharmacology & Toxicology, Biochemistry; Intellectual Property "
"Join COO David Aguilar Ph.D., Research Scientist Alfred Gallegos, and Science Advisor Mark Stevens at #AARC2024 to discover our groundbreaking gene-editing platform that will revolutionize how we treat Colon Cancer."
Another University of Arizona guy.
https://www.linkedin.com/in/mark-stevens-phd-810167a/
Impressive Resume, imo. Now also works for US Dept. of Commerce.
Skills include Cancer Research:
https://www.linkedin.com/in/mark-stevens-phd-810167a/details/skills/
https://www.linkedin.com/in/mark-stevens-phd-810167a/details/publications/
You may have mentioned Mark Stevens before? He also has a past U of A background? Thx. $shmn
— Dave (@hardlesson1) March 28, 2024
Join COO David Aguilar Ph.D., Research Scientist Alfred Gallegos, and Science Advisor Mark Stevens at #AARC2024 to discover our groundbreaking gene-editing platform that will revolutionize how we treat Colon Cancer.
— SOHM, Inc. (@sohminc) March 28, 2024
More: https://t.co/tcmjjGEEW1#SOHMInc #ABBIE $SHMN pic.twitter.com/RzYwx8X4yy